Search

Your search keyword '"Ram S. Bharath"' showing total 14 results
Start Over Author "Ram S. Bharath"
14 results on '"Ram S. Bharath"'

1. Outcomes of patients with hematologic malignancies and COVID-19 from the Hematologic Cancer Registry of India

Author

Arihant Jain, Lingaraj Nayak, Uday Prakash Kulkarni, Nikita Mehra, Uday Yanamandra, Smita Kayal, Sharat Damodar, Joseph M. John, Prashant Mehta, Suvir Singh, Pritesh Munot, Sushil Selvarajan, Venkatraman Radhakrishnan, Deepesh Lad, Rajan Kapoor, Biswajit Dubashi, Ram S. Bharath, Hasmukh Jain, P. K. Jayachandran, Jeyaseelan Lakshmanan, Thenmozhi Mani, Jayashree Thorat, Satyaranjan Das, Omprakash Karunamurthy, Biju George, Manju Sengar, and Pankaj Malhotra

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2022
Full Text
View/download PDF

3. Early Results from a Phase-2 Study of Varnimcabtagene Autoleucel (IMN-003A), a First-in-India Industry CD19-Directed CAR-T Cell Therapy with Fractionated Infusions for Patients with Relapsed and/or Refractory B Cell Malignancies (IMAGINE Study)

Author

Damodar, Sharat, primary, Bhat, Sunil, additional, Nayak, Akshatha, additional, Mallya, Pooja, additional, Ram S, Bharath, additional, Joshi, Ravi, additional, MB, Deepak, additional, Chougule, Sudarshan, additional, Joseph, Anne Roshan, additional, Jakka, Gopinadh, additional, Dhar, Sudeshna, additional, Kumar MG, Arun, additional, Palanisamy, Murugan, additional, Elluru, Sri Ramulu, additional, Akheel, Mohammed Manzoor, additional, Anand, Arun, additional, and Kamat, Anil, additional

Published
2022
Full Text
View/download PDF

4. Real World Data on Unique Challenges and Outcomes of Older Patients with AML from Resource Limited Settings: Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC)

Author

Singh, Suvir, primary, Lionel, Sharon, additional, Jain, Hasmukh, additional, Nayak, Lingaraj, additional, Selvarajan, Sushil, additional, Samuel, Prasanna, additional, Ahmed, Rayaz, additional, Agrawal, Narendra, additional, DS, Pavitra, additional, Byreddy, Poojitha, additional, M John, Joseph, additional, Mishra, Kundan, additional, Kumar, Suman, additional, Paul, Mobin, additional, Abraham, Latha, additional, Kayal, Smita, additional, Ganesan, Prasanth, additional, Philip, Chepsy C, additional, Das, Damodar, additional, Vasudevan, Sreeraj, additional, Mehta, Prashant, additional, PK, Jayachandran, additional, Raghavan, Vineetha, additional, Bala, Stalin Chowdary, additional, Ram S, Bharath, additional, Majumdar, Swaratika, additional, Rajendra, Akhil, additional, Prakash, Om, additional, U, Barath, additional, Bagal, Bhausaheb, additional, Abraham, Aby, additional, Kapoor, Rajan, additional, Bhurani, Dinesh, additional, Sengar, Manju, additional, and Mathews, Vikram, additional

Published
2022
Full Text
View/download PDF

5. Fludrabine Treosulfan Conditioning Regimen Appears Safe and Effective in Patients with Acute Myeloid Leukemia(AML) and Myelodysplastic Syndrome (MDS) Undergoing Allogenic Hematopoietic Stem Cell Transplantation (HSCT)

Author

Yadav, Chitresh, primary, Damodar, Sharat, additional, Bhargava, Rahul, additional, Haridas, Nikhil Krishna, additional, Jaishetwar, Ganesh S, additional, Paul, Mobin, additional, Ram S, Bharath, additional, Nayak, Akshatha, additional, Harimadhavan, Monisha, additional, Mangal, Rohit, additional, Unni, Manoj, additional, Ganapathy, Rema, additional, Yawalkar, Rashmi Suresh, additional, Agrawal, Shreya Gopal, additional, Mony, Ullas, additional, Kartha, Nivedhitha, additional, and Sidharthan, Neeraj, additional

Published
2022
Full Text
View/download PDF

6. Response, Peak and Persistence of Varnimcabtagene Autoleucel (IMN-003A), First-in-India Industry CD19-Directed CAR-T Cell Therapy, with Fractionated Infusions for Patients with Relapsed and/or Refractory B Cell Malignancies: Early Results (IMAGINE Study)

Author

Bhat, Sunil, primary, Damodar, Sharat, additional, Mallya, Pooja, additional, Nayak, Akshatha, additional, Joshi, Ravi, additional, Ram S, Bharath, additional, Chougule, Sudarshan, additional, MB, Deepak, additional, Jakka, Gopinadh, additional, Dhar, Sudeshna, additional, Joseph, Anne Roshan, additional, Kumar MG, Arun, additional, Palanisamy, Murugan, additional, Kumar, Jeetendra, additional, Soares, Melina, additional, Arasu, Pallavi, additional, Elluru, Sri Ramulu, additional, Akheel, Mohammed Manzoor, additional, and Kamat, Anil, additional

Published
2022
Full Text
View/download PDF

7. Induction Related Mortality Score in Acute Myeloid Leukemia: Prospective Validation Study (pRISM) of the Hematology Cancer Consortium (HCC)

Author

Kayal, Smita, primary, Jain, Hasmukh, additional, Nayak, Lingaraj, additional, Thorat, Jayashree, additional, Bhattacharyya, Jina, additional, Das, Damodar, additional, Talukdar, Sewali Deka, additional, Bhurani, Dinesh, additional, Ahmed, Rayaz, additional, Agrawal, Narendra, additional, Biswajit, Dubashi, additional, Ganesan, Prasanth, additional, Nair, Chandran K., additional, Raghavan, Vineetha, additional, A, Manuprasad, additional, Kulkarni, Uday, additional, Selvarajan, Sushil, additional, PK, Jayachandran, additional, Karunakaran, Parathan, additional, Gundeti, Sadashivudu, additional, Mishra, Kundan, additional, Damodar, Sharat, additional, Ram S, Bharath, additional, Sharma, Atul, additional, Singh, Suvir, additional, John, M. Joseph, additional, Prakash, Gaurav, additional, Saldanha, Smitha Carol, additional, Philip, Chepsy C, additional, Mehta, Prashant, additional, Mani, Thenmozhi, additional, Prakash, Om, additional, S, Marimuthu, additional, Lakshmanan, Jeyaseelan, additional, Sengar, Manju, additional, Mathews, Vikram, additional, and Kapoor, Rajan, additional

Published
2022
Full Text
View/download PDF

9. Covid-19 Infection in Hematological Malignancies: Registry Data from India

Author

Jain, Arihant, primary, Nayak, Lingaraj, additional, Kulkarni, Uday Prakash, additional, Mehra, Nikita, additional, Yanamandra, Uday, additional, Kayal, Smita, additional, Damodar, Sharat, additional, M John, Joseph, additional, Singh, Suvir, additional, Mehta, Prashant, additional, Munot, Pritesh, additional, Selvarajan, Sushil, additional, Radhakrishnan, Venkatraman, additional, Kapoor, Rajan, additional, Dubashi, Biswajit, additional, Ram S, Bharath, additional, Jain, Hasmukh, additional, PK, Jayachandran, additional, Lakshmanan, Jeyaseelan, additional, Mani, Thenmozhi, additional, Prakash, Om, additional, Thorat, Jayashree, additional, Das, Satyaranjan, additional, George, Biju, additional, Lad, Deepesh, additional, and Malhotra, Pankaj, additional

Published
2021
Full Text
View/download PDF

10. Plasmablastic Myeloma-A Diagnostic Dilemma.

Author

KOMARAVELLI, SHIVA KUMAR, DEEPAK, M. B., RAM, S. BHARATH, DALAL, HAMZA, and NATARAJ, K. S.

Subjects
IMMUNOGLOBULIN light chains, MULTIPLE myeloma, PLASMA cell diseases, BONE marrow, HIV, LYMPHADENITIS, CANCER fatigue
Abstract

Plasmablastic neoplasms comprise various haematolymphoid tumours with plasmablastic morphology which includes Plasmablastic Myeloma (PBM) and Plasmablastic Lymphoma (PBL). Distinguishing these two entities remains a major diagnostic challenge. In view of Epstein Barr Virus (EBV)-Encoded RNA (EBER) negativity, Human Immunodeficiency Virus (HIV) negativity, high Serum Free Light Chain (SFLC) assay and absence of hypermetabolic lymphadenopathy, a final diagnosis of PBM was made. This report is about a 55-year-old lady who presented with fatigue, significant loss of weight, and appetite. She had mild enlargement of the liver, spleen and no significant lymphadenopathy. There were atypical cells in peripheral blood. Bone marrow evaluation showed 51% atypical mononuclear cells. Flow cytometry was negative for acute leukaemia diagnostic markers. Immunohistochemistry (IHC) on the bone marrow biopsy revealed positivity for Cluster of Differentiation (CD) 138, Multiple Myeloma 1 (MUM1) with kappa light chain restriction and negative for EBER. The free light chain showed a kappa:lambda light chain ratio of 28,885 (0.26-1.65). The diagnosis of PBM was made and she was started on a daratumumab-based immunotherapy regimen. She achieved complete remission after induction with Measurable Residual Disease (MRD) <0.01%. She is presently doing well on follow-up with the disease in remission status. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results